Eliem Therapeutics, Inc.
ELYM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9 | $7 | $17 | $9 |
| G&A Expenses | $6 | $4 | $6 | $8 |
| SG&A Expenses | $6 | $4 | $6 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $52 |
| Operating Expenses | $15 | $11 | $23 | $69 |
| Operating Income | -$15 | -$11 | -$23 | -$63 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $2 | $0 |
| Pre-Tax Income | -$13 | -$9 | -$21 | -$8 |
| Tax Expense | $0 | $0 | $0 | $3 |
| Net Income | -$13 | -$9 | -$21 | -$8 |
| % Margin | – | – | – | – |
| EPS | -0.19 | -0.13 | -0.31 | 0.47 |
| % Growth | -46.2% | 58.1% | -166% | – |
| EPS Diluted | -0.19 | -0.13 | -0.31 | 0.47 |
| Weighted Avg Shares Out | 68 | 68 | 67 | 67 |
| Weighted Avg Shares Out Dil | 68 | 68 | 67 | 67 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $0 | -$3 |
| Interest Expense | $0 | $0 | $0 | -$1 |
| Depreciation & Amortization | $0 | $0 | $0 | -$6 |
| EBITDA | -$13 | -$11 | -$23 | -$11 |
| % Margin | – | – | – | – |